vs
Side-by-side financial comparison of Bandwidth Inc. (BAND) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Bandwidth Inc. is the larger business by last-quarter revenue ($208.8M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). Bandwidth Inc. runs the higher net margin — 1.9% vs 1.6%, a 0.3% gap on every dollar of revenue. On growth, Bandwidth Inc. posted the faster year-over-year revenue change (20.1% vs 5.0%). Over the past eight quarters, Bandwidth Inc.'s revenue compounded faster (9.7% CAGR vs -0.2%).
Bandwidth Inc. is a communications platform as a service company. It sells software application programming interfaces for voice, text messaging and emergency services, using its own global IP voice network.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
BAND vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $208.8M | $177.4M |
| Net Profit | $4.0M | $2.9M |
| Gross Margin | 37.3% | — |
| Operating Margin | 60.5% | 3.9% |
| Net Margin | 1.9% | 1.6% |
| Revenue YoY | 20.1% | 5.0% |
| Net Profit YoY | 200.0% | — |
| EPS (diluted) | $-0.08 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $208.8M | $177.4M | ||
| Q4 25 | $207.7M | $196.9M | ||
| Q3 25 | $191.9M | $179.5M | ||
| Q2 25 | $180.0M | $181.1M | ||
| Q1 25 | $174.2M | $168.9M | ||
| Q4 24 | $210.0M | $187.3M | ||
| Q3 24 | $193.9M | $168.6M | ||
| Q2 24 | $173.6M | $178.0M |
| Q1 26 | $4.0M | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-1.2M | $5.4M | ||
| Q2 25 | $-4.9M | $-4.8M | ||
| Q1 25 | $-3.7M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $413.0K | $-143.5M | ||
| Q2 24 | $4.1M | $18.9M |
| Q1 26 | 37.3% | — | ||
| Q4 25 | 37.6% | 79.5% | ||
| Q3 25 | 38.5% | 80.9% | ||
| Q2 25 | 39.8% | 77.4% | ||
| Q1 25 | 41.0% | 79.7% | ||
| Q4 24 | 36.4% | 78.7% | ||
| Q3 24 | 37.7% | 76.9% | ||
| Q2 24 | 37.3% | 75.1% |
| Q1 26 | 60.5% | 3.9% | ||
| Q4 25 | -1.9% | 1.2% | ||
| Q3 25 | -1.0% | 3.5% | ||
| Q2 25 | -2.1% | 4.7% | ||
| Q1 25 | -2.7% | 1.2% | ||
| Q4 24 | -1.3% | 13.2% | ||
| Q3 24 | -0.5% | -82.8% | ||
| Q2 24 | -3.5% | 15.9% |
| Q1 26 | 1.9% | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.6% | 3.0% | ||
| Q2 25 | -2.7% | -2.7% | ||
| Q1 25 | -2.1% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.2% | -85.1% | ||
| Q2 24 | 2.3% | 10.6% |
| Q1 26 | $-0.08 | $0.07 | ||
| Q4 25 | $-0.10 | $0.05 | ||
| Q3 25 | $-0.04 | $0.12 | ||
| Q2 25 | $-0.16 | $-0.11 | ||
| Q1 25 | $-0.13 | $0.10 | ||
| Q4 24 | $0.27 | $0.38 | ||
| Q3 24 | $0.01 | $-3.11 | ||
| Q2 24 | $-0.17 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $47.3M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $405.7M | $653.9M |
| Total Assets | $984.2M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $47.3M | $144.3M | ||
| Q4 25 | $111.3M | $238.4M | ||
| Q3 25 | $80.4M | $246.3M | ||
| Q2 25 | $68.1M | $445.9M | ||
| Q1 25 | $41.7M | $493.6M | ||
| Q4 24 | $83.8M | $484.6M | ||
| Q3 24 | $79.9M | $453.8M | ||
| Q2 24 | $76.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $405.7M | $653.9M | ||
| Q4 25 | $400.0M | $693.1M | ||
| Q3 25 | $392.7M | $727.2M | ||
| Q2 25 | $384.5M | $757.8M | ||
| Q1 25 | $345.4M | $798.5M | ||
| Q4 24 | $312.5M | $778.3M | ||
| Q3 24 | $336.6M | $749.6M | ||
| Q2 24 | $307.4M | $879.3M |
| Q1 26 | $984.2M | $1.2B | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $964.4M | $1.6B | ||
| Q4 24 | $989.2M | $1.6B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $1.0B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | — |
| Free Cash FlowOCF − Capex | $-1.0M | — |
| FCF MarginFCF / Revenue | -0.5% | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $38.6M | $43.7M | ||
| Q3 25 | $22.2M | $60.8M | ||
| Q2 25 | $31.7M | $12.0M | ||
| Q1 25 | $-3.1M | $35.5M | ||
| Q4 24 | $36.5M | $33.1M | ||
| Q3 24 | $20.5M | $53.9M | ||
| Q2 24 | $24.4M | $53.2M |
| Q1 26 | $-1.0M | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | -0.5% | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 49.55× | — | ||
| Q2 24 | 6.03× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAND
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
